Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference

Aron Goldhirsch, Alan S. Coates, Marco Colleoni, Monica Castiglione-Gertsch, Richard D. Gelber

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Purpose: Adjuvant cytotoxics prolong disease-free survival (DFS) and overall survival (OS) in patients with operable breast cancer. The first reported effective adjuvant combination regimen consisted of oral cyclophosphamide on days 1 to 14 with intravenous methotrexate and fluorouracil on days 1 and 8, repeated every 28 days (classical CMF). These drugs have since been extensively used with or without endocrine therapies and/or other cytotoxic agents. Although doses and schedules have varied widely, the combination of these three drugs is generically referred to as CMF. Results: Reducing the dose and/or altering the schedule of CMF have compromised its efficacy in metastatic breast cancer. Reduction below standard dose of a similar regimen also gave inferior results in the adjuvant setting. Conclusion: Details of dose and schedule may therefore explain part of rite heterogeneity of results observed with CMF Particular controversy surrounds the contribution of CMF in postmenopausal women who are also receiving tamoxifen (TAM). However, the trials that demonstrated a significant benefit for the addition of CMF to TAM, even in postmenopausal women with estrogen receptor-positive tumors, used classical CMF. Therefore, adherence to the classical dose and schedule is recommended when CMF is used in adjuvant therapy.

Original languageEnglish
Pages (from-to)1358-1362
Number of pages5
JournalJournal of Clinical Oncology
Volume16
Issue number4
Publication statusPublished - Apr 1998

Fingerprint

Methotrexate
Fluorouracil
Cyclophosphamide
Appointments and Schedules
Breast Neoplasms
Tamoxifen
Cytotoxins
Drug Combinations
Therapeutics
Estrogen Receptors
Disease-Free Survival
Survival
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant chemoendocrine therapy in postmenopausal breast cancer : Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. / Goldhirsch, Aron; Coates, Alan S.; Colleoni, Marco; Castiglione-Gertsch, Monica; Gelber, Richard D.

In: Journal of Clinical Oncology, Vol. 16, No. 4, 04.1998, p. 1358-1362.

Research output: Contribution to journalArticle

@article{324f9622cbea477fa9948ae516803cf1,
title = "Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference",
abstract = "Purpose: Adjuvant cytotoxics prolong disease-free survival (DFS) and overall survival (OS) in patients with operable breast cancer. The first reported effective adjuvant combination regimen consisted of oral cyclophosphamide on days 1 to 14 with intravenous methotrexate and fluorouracil on days 1 and 8, repeated every 28 days (classical CMF). These drugs have since been extensively used with or without endocrine therapies and/or other cytotoxic agents. Although doses and schedules have varied widely, the combination of these three drugs is generically referred to as CMF. Results: Reducing the dose and/or altering the schedule of CMF have compromised its efficacy in metastatic breast cancer. Reduction below standard dose of a similar regimen also gave inferior results in the adjuvant setting. Conclusion: Details of dose and schedule may therefore explain part of rite heterogeneity of results observed with CMF Particular controversy surrounds the contribution of CMF in postmenopausal women who are also receiving tamoxifen (TAM). However, the trials that demonstrated a significant benefit for the addition of CMF to TAM, even in postmenopausal women with estrogen receptor-positive tumors, used classical CMF. Therefore, adherence to the classical dose and schedule is recommended when CMF is used in adjuvant therapy.",
author = "Aron Goldhirsch and Coates, {Alan S.} and Marco Colleoni and Monica Castiglione-Gertsch and Gelber, {Richard D.}",
year = "1998",
month = "4",
language = "English",
volume = "16",
pages = "1358--1362",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Adjuvant chemoendocrine therapy in postmenopausal breast cancer

T2 - Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference

AU - Goldhirsch, Aron

AU - Coates, Alan S.

AU - Colleoni, Marco

AU - Castiglione-Gertsch, Monica

AU - Gelber, Richard D.

PY - 1998/4

Y1 - 1998/4

N2 - Purpose: Adjuvant cytotoxics prolong disease-free survival (DFS) and overall survival (OS) in patients with operable breast cancer. The first reported effective adjuvant combination regimen consisted of oral cyclophosphamide on days 1 to 14 with intravenous methotrexate and fluorouracil on days 1 and 8, repeated every 28 days (classical CMF). These drugs have since been extensively used with or without endocrine therapies and/or other cytotoxic agents. Although doses and schedules have varied widely, the combination of these three drugs is generically referred to as CMF. Results: Reducing the dose and/or altering the schedule of CMF have compromised its efficacy in metastatic breast cancer. Reduction below standard dose of a similar regimen also gave inferior results in the adjuvant setting. Conclusion: Details of dose and schedule may therefore explain part of rite heterogeneity of results observed with CMF Particular controversy surrounds the contribution of CMF in postmenopausal women who are also receiving tamoxifen (TAM). However, the trials that demonstrated a significant benefit for the addition of CMF to TAM, even in postmenopausal women with estrogen receptor-positive tumors, used classical CMF. Therefore, adherence to the classical dose and schedule is recommended when CMF is used in adjuvant therapy.

AB - Purpose: Adjuvant cytotoxics prolong disease-free survival (DFS) and overall survival (OS) in patients with operable breast cancer. The first reported effective adjuvant combination regimen consisted of oral cyclophosphamide on days 1 to 14 with intravenous methotrexate and fluorouracil on days 1 and 8, repeated every 28 days (classical CMF). These drugs have since been extensively used with or without endocrine therapies and/or other cytotoxic agents. Although doses and schedules have varied widely, the combination of these three drugs is generically referred to as CMF. Results: Reducing the dose and/or altering the schedule of CMF have compromised its efficacy in metastatic breast cancer. Reduction below standard dose of a similar regimen also gave inferior results in the adjuvant setting. Conclusion: Details of dose and schedule may therefore explain part of rite heterogeneity of results observed with CMF Particular controversy surrounds the contribution of CMF in postmenopausal women who are also receiving tamoxifen (TAM). However, the trials that demonstrated a significant benefit for the addition of CMF to TAM, even in postmenopausal women with estrogen receptor-positive tumors, used classical CMF. Therefore, adherence to the classical dose and schedule is recommended when CMF is used in adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=0031947876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031947876&partnerID=8YFLogxK

M3 - Article

C2 - 9552037

AN - SCOPUS:0031947876

VL - 16

SP - 1358

EP - 1362

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -